Nvidia, which importantly commands an S&P 500 weighting of around 7%, touched an intraday high near $144.50 on Tuesday. That breakout to a fresh record was closely-watched says Jonathan Krinsky, chief ...

BTIG analyst Carl Reichardt raised the firm’s price target on PulteGroup (PHM) to $156 from $139 and keeps a Buy rating on the shares.

The October 22 report on Hoka noted signs that the running footwear brand’s multi-year growth is moderating. The firm also ...

BTIG analysts downgraded Deckers Outdoor (NYSE:DECK) from Buy to Neutral on Tuesday, citing signs of slowing growth across ...

The U.S. stock market is now approaching the end of what is typically the most volatile period of a presidential election ...

BTIG raised the firm’s price target on MicroStrategy (MSTR) to $240 from $180 and keeps a Buy rating on the shares. The implied bitcoin ...

BTIG’s Jonathan Krinsky made a case that the S&P 500 utility sector may be poised for a downward correction. “We think it's ...

BTIG analyst sees upside in Affirm stock to $68. The fintech is fully committed to soon becoming a profitable company.

BTIG Research reissued their buy rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research note issued to investors on Friday morning, Marketbeat.com reports. BTIG Research currently has ...

On Monday, BTIG reiterated its Sell rating on American Express (NYSE:AXP), maintaining the $230.00 price target for the company's shares. The firm's analyst pointed out that while the rationale for ...

As of September 25, 2024, the average one-year price target for Apyx Medical is $3.57/share. The forecasts range from a low of $2.02 to a high of $6.30. The average price target represents an ...

On Monday, BTIG reiterated a Neutral rating on Ally Financial (NYSE: NYSE:ALLY) shares, citing challenges in the near term regarding the company's credit trends and net interest margins.